The vehicle, which was significantly oversubscribed, was led by Hayfin Capital Management and supported by institutional investors including BNP Paribas AM and Altamar CAM. The structure provides liquidity to existing limited partners at three times invested capital, while allowing Alantra to retain exposure to a high-conviction asset. The transaction also introduces Merieux Equity Partners as a 20% minority shareholder through its buyout fund, Merieux Participations 4. The addition of a specialist healthcare investor signals a deliberate shift from build-and-integrate to scale-and-expand, as Health in Code prepares to accelerate its international footprint. Founded in 2020 through the combination of Health in Code, Imegen, Genycell Biotech, and later Genologica, the business has developed an integrated clinical genomics platform serving hospitals and healthcare professionals in more than 30 countries. The company combines next-generation sequencing services, diagnostic kits, and...
learn more
